These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 31066985)

  • 1. Long-Term Retention in an Outpatient Behavioral Health Clinic With Buprenorphine.
    Montalvo C; Stankiewicz B; Brochier A; Henderson DC; Borba CPC
    Am J Addict; 2019 Sep; 28(5):339-346. PubMed ID: 31066985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis.
    Litz M; Leslie D
    Am J Addict; 2017 Dec; 26(8):859-863. PubMed ID: 29143483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients.
    Lee CS; Rosales R; Stein MD; Nicholls M; O'Connor BM; Loukas Ryan V; Davis EA
    Am J Addict; 2019 Sep; 28(5):409-412. PubMed ID: 31251426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
    Dayal P; Balhara YPS
    J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population.
    Hallowell BD; Chambers LC; Samuels EA; Bratberg J; McDonald J; Nitenson A; Onyejekwe C; Beaudoin FL
    Drug Alcohol Depend; 2022 Dec; 241():109680. PubMed ID: 36335834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
    Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
    Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers.
    Haddad MS; Zelenev A; Altice FL
    J Urban Health; 2015 Feb; 92(1):193-213. PubMed ID: 25550126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of early dropout in outpatient buprenorphine/naloxone treatment.
    Marcovitz DE; McHugh RK; Volpe J; Votaw V; Connery HS
    Am J Addict; 2016 Sep; 25(6):472-7. PubMed ID: 27442456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs.
    Damian AJ; Mendelson T; Agus D
    Addict Behav; 2017 Oct; 73():129-132. PubMed ID: 28505488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating addiction medicine into rural primary care: Strategies and initial outcomes.
    Logan DE; Lavoie AM; Zwick WR; Kunz K; Bumgardner MA; Molina Y
    J Consult Clin Psychol; 2019 Oct; 87(10):952-961. PubMed ID: 31556671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.
    Shcherbakova N; Tereso G; Spain J; Roose RJ
    Ann Pharmacother; 2018 May; 52(5):405-414. PubMed ID: 29302989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
    Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
    Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten Years of Experience With Buprenorphine in a Private Psychiatric Outpatient Practice.
    Feder R
    Am J Addict; 2020 Nov; 29(6):508-514. PubMed ID: 32410327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial.
    Campbell ANC; Barbosa-Leiker C; Hatch-Maillette M; Mennenga SE; Pavlicova M; Scodes J; Saraiya T; Mitchell SG; Rotrosen J; Novo P; Nunes EV; Greenfield SF
    Am J Addict; 2018 Sep; 27(6):465-470. PubMed ID: 30106494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.